DKFZ 6 records found  Search took 0.00 seconds. 
DBCoverage [DKFZ-2022-02484] Journal Article
; ; ; et al
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.
Cancer heterogeneity at the proteome level may explain differences in therapy response and prognosis beyond the currently established genomic and transcriptomic-based diagnostics. The relevance of proteomics for disease classifications remains to be established in clinically heterogeneous cancer entities such as chronic lymphocytic leukemia (CLL). [...]
[DKFZ-2017-06127] Journal Article
; ; ; et al
Highly efficient destruction of squamous carcinoma cells of the head and neck by photochemical internalization of Ranpirnase.
Photochemical Internalization is a novel drug delivery technology for cancer treatment based on the principle of Photodynamic Treatment. Using a photosensitizer that locates in endocytic vesicles membranes of tumor cells, Photochemical internalization enables cytosolic release of endocytosed antitumor agents in a site-specific manner. [...]
[DKFZ-2017-03138] Journal Article
; ; ; et al
A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor.
Due to its frequent overexpression in a variety of solid tumors the epidermal growth factor receptor (EGFR) is a well-established target for therapeutic interventions in epithelial cancers. In order to target EGFR in head and neck cancer, we have generated a ribonuclease (RNase) fusion protein comprising a humanized anti-EGFR antibody single-chain Fv fragment (scFv) and Ranpirnase, an RNase from Rana pipiens. [...]
[DKFZ-2017-02900] Journal Article
; ; ; et al
An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.
Cancer letters 357(1), 364 - 373 () [10.1016/j.canlet.2014.11.054]  GO
Cytotoxic ribonucleases such as the leopard frog derivative Ranpirnase (Onconase(®)) have emerged as a valuable new class of cancer therapeutics. Clinical trials employing single agent Ranpirnase in cancer patients have demonstrated significant clinical activity and surprisingly low immunogenicity. [...]

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.